Inhibitor of the non-structural protein 2 protease shows promising efficacy in mouse models of chikungunya.

Chikungunya virus (CHIKV) is responsible for the most endemic alphavirus infections called Chikungunya. The endemicity of Chikungunya has increased over the past two decades, and it is a pathogen with pandemic potential. There is currently no approved direct-acting antiviral to treat the disease. As part of our antiviral drug discovery program focused on alphaviruses and the non-structural protein 2 protease, we discovered that J12 and J13 can inhibit CHIKV nsP2 protease and block the replication of CHIKV in cell cultures. Both compounds are metabolically stable to human liver microsomal and S9 enzymes. J13 has excellent oral bioavailability in pharmacokinetics studies in mice and ameliorated Chikungunya symptoms in preliminary efficacy studies in mice. J13 exhibited an excellent safety profile in in vitro safety pharmacology and off-target screening assays, making J13 and its analogs good candidates for drug development against Chikungunya. [Display omitted] • NsP2 protease inhibitors with antiviral activity were investigated in this work. • Vinyl sulfone-based inhibitors were discovered to be active against Chikungunya virus. • The drug lead J13 has excellent oral bioavailability and off-target selectivity. • The drug lead, J13 , showed promising in vivo efficacy in mouse models. [ABSTRACT FROM AUTHOR]